Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2017 (2017), Article ID 5047898, 8 pages
https://doi.org/10.1155/2017/5047898
Research Article

Autoantibodies to NR2A Peptide of the Glutamate/NMDA Receptor in Patients with Seizure Disorders in Neuropsychiatric Systemic Lupus Erythematosus

1Guangdong No. 2 Provincial People’s Hospital, Courtyard No. 466, Middle Xingang Road, Haizhu District, Guangzhou 510317, China
2Department of Neurology, Nanfang Hospital, Southern Medical University, No. 1838 North Guangzhou Avenue, Guangzhou 510515, China
3TEDA International Cardiovascular Hospital, Medical College, Nankai University, Tianjin, China
4School of Public Health, Southern Medical University, No. 1023 South Shatai Rd., Guangzhou, Guangdong 510515, China
5Department of Histology and Embryology, School of Basic Medical Sciences, Southern Medical University, Guangzhou 510515, China
6Nanfang Hospital, Southern Medical University, Guangzhou 510515, China
7Department of Rheumatology, Nanfang Hospital, Southern Medical University, No. 1838 North Guangzhou Avenue, Guangzhou 510515, China

Correspondence should be addressed to Qin Huang; moc.liamxof@qhizniq

Received 4 September 2016; Accepted 15 December 2016; Published 5 January 2017

Academic Editor: Luc Vallières

Copyright © 2017 Yan Yang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. T. Shirai and S. Hirose, “Molecular pathogenesis of SLE,” Springer Seminars in Immunopathology, vol. 28, no. 2, pp. 79–82, 2006. View at Publisher · View at Google Scholar · View at Scopus
  2. H. Ainiala, J. Loukkola, J. Peltola et al., “The prevalence of neuropsychiatric syndromes in systemic lupus erythematosus,” Neurology, vol. 58, no. 12, p. 1867, 2002. View at Google Scholar
  3. G. Sanna, M. L. Bertolaccini, M. J. Cuadrado et al., “Neuropsychiatric manifestations in systemic lupus erythematosus: prevalence and association with antiphospholipid antibodies,” Journal of Rheumatology, vol. 30, no. 5, pp. 985–992, 2003. View at Google Scholar · View at Scopus
  4. M. H. Liang, M. Corzillius, S.-C. Bae et al., “The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes,” Arthritis & Rheumatism, vol. 42, no. 4, pp. 599–608, 1999. View at Publisher · View at Google Scholar · View at Scopus
  5. L. V. Kalia, S. K. Kalia, and M. W. Salter, “NMDA receptors in clinical neurology: excitatory times ahead,” The Lancet Neurology, vol. 7, no. 8, pp. 742–755, 2008. View at Publisher · View at Google Scholar · View at Scopus
  6. E. A. Waxman and D. R. Lynch, “N-methyl-D-aspartate receptor subtypes: multiple roles in excitotoxicity and neurological disease,” Neuroscientist, vol. 11, no. 1, pp. 37–49, 2005. View at Publisher · View at Google Scholar · View at Scopus
  7. J. T. Coyle, “Glutamate and schizophrenia: beyond the dopamine hypothesis,” Cellular and molecular neurobiology, vol. 26, no. 4–6, pp. 365–384, 2006. View at Google Scholar · View at Scopus
  8. C. G. Lau and R. S. Zukin, “NMDA receptor trafficking in synaptic plasticity and neuropsychiatric disorders,” Nature Reviews Neuroscience, vol. 8, no. 6, pp. 413–426, 2007. View at Publisher · View at Google Scholar · View at Scopus
  9. M. B. Lauvsnes and R. Omdal, “Systemic lupus erythematosus, the brain, and anti-NR2 antibodies,” Journal of Neurology, vol. 259, no. 4, pp. 622–629, 2012. View at Publisher · View at Google Scholar · View at Scopus
  10. C. J. McGinnity, M. J. Koepp, A. Hammers et al., “NMDA receptor binding in focal epilepsies,” Journal of Neurology, Neurosurgery & Psychiatry, vol. 86, no. 10, pp. 1150–1157, 2015. View at Publisher · View at Google Scholar · View at Scopus
  11. E. S. Husebye, Z. M. Sthoeger, M. Dayan et al., “Autoantibodies to a NR2A peptide of the glutamate/NMDA receptor in sera of patients with systemic lupus erythematosus,” Annals of the Rheumatic Diseases, vol. 64, no. 8, pp. 1210–1213, 2005. View at Publisher · View at Google Scholar · View at Scopus
  12. E. L. Smith and R. H. Shmerling, “The American College of Rheumatology criteria for the classification of systemic lupus erythematosus: strengths, weaknesses, and opportunities for improvement,” Lupus, vol. 8, no. 8, pp. 586–595, 1999. View at Publisher · View at Google Scholar · View at Scopus
  13. J. G. Hanly, “ACR classification criteria for systemic lupus erythematosus: limitations and revisions to neuropsychiatric variables,” Lupus, vol. 13, no. 11, pp. 861–864, 2004. View at Publisher · View at Google Scholar · View at Scopus
  14. Commission on Classification and Terminology of the International League Against Epilepsy, “Proposal for revised classification of epilepsies and epileptic syndromes. Commission on Classification and Terminology of the International League Against Epilepsy,” Epilepsia, vol. 30, no. 4, pp. 389–399, 1989. View at Google Scholar
  15. “Guidelines for epidemiologic studies on epilepsy. Commission on Epidemiology and Prognosis, International League Against Epilepsy,” Epilepsia, vol. 34, no. 4, pp. 592–596, 1993.
  16. P. Kwan and M. J. Brodie, “Early identification of refractory epilepsy,” New England Journal of Medicine, vol. 342, no. 5, pp. 314–319, 2000. View at Publisher · View at Google Scholar · View at Scopus
  17. K. Elkon, S. Skelly, A. Parnassa et al., “Identification and chemical synthesis of a ribosomal protein antigenic determinant in systemic lupus erythematosus,” Proceedings of the National Academy of Sciences of the United States of America, vol. 83, no. 19, pp. 7419–7423, 1986. View at Publisher · View at Google Scholar · View at Scopus
  18. L. A. Degiorgio, K. N. Konstantinov, S. C. Lee, J. A. Hardin, B. T. Volpe, and B. Diamond, “A subset of lupus anti-DNA antibodies cross-reacts with the NR2 glutamate receptor in systemic lupus erythematosus,” Nature Medicine, vol. 7, no. 11, pp. 1189–1193, 2001. View at Publisher · View at Google Scholar · View at Scopus
  19. Y. Arinuma, T. Yanagida, and S. Hirohata, “Association of cerebrospinal fluid anti-NR2 glutamate receptor antibodies with diffuse neuropsychiatric systemic lupus erythematosus,” Arthritis & Rheumatism, vol. 58, no. 4, pp. 1130–1135, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. D. T. Monaghan, R. J. Bridges, and C. W. Cotman, “The excitatory amino acid receptors: their classes, pharmacology, and distinct properties in the function of the central nervous system,” Annual Review of Pharmacology and Toxicology, vol. 29, pp. 365–402, 1989. View at Publisher · View at Google Scholar · View at Scopus
  21. L. P. Wollmuth and A. I. Sobolevsky, “Structure and gating of the glutamate receptor ion channel,” Trends in Neurosciences, vol. 27, no. 6, pp. 321–328, 2004. View at Publisher · View at Google Scholar · View at Scopus
  22. C. Chiamulera, S. Costa, and A. Reggiani, “Effect of NMDA- and strychnine-insensitive glycine site antagonists on NMDA-mediated convulsions and learning,” Psychopharmacology, vol. 102, no. 4, pp. 551–552, 1990. View at Publisher · View at Google Scholar · View at Scopus
  23. M. Scerrati, M. Onofrj, L. Pacifici, P. Pola, M. T. Ramacci, and G. F. Rossi, “Electrocerebral and behavioural analysis of systemic kainic acid-induced epilepsy in the rat,” Drugs under Experimental & Clinical Research, vol. 12, no. 8, pp. 671–680, 1986. View at Google Scholar · View at Scopus
  24. J. Louvel, R. Pumain, M. Avoli, I. Kurcewicz, B. Devaux, and J. P. Chodkiewicz, “GABAA inhibition controls the calcium flows during NMDA-dependent epileptiform activity in human epileptogenic neocortex,” Epilepsy Research. Supplement, vol. 12, pp. 293–300, 1996. View at Google Scholar · View at Scopus
  25. I. Cohen, V. Navarro, S. Clemenceau, M. Baulac, and R. Miles, “On the origin of interictal activity in human temporal lobe epilepsy in vitro,” Science, vol. 298, no. 5597, pp. 1418–1421, 2002. View at Publisher · View at Google Scholar · View at Scopus
  26. G. Huberfeld, L. M. De La Prida, J. Pallud et al., “Glutamatergic pre-ictal discharges emerge at the transition to seizure in human epilepsy,” Nature Neuroscience, vol. 14, no. 5, pp. 627–634, 2011. View at Publisher · View at Google Scholar · View at Scopus
  27. M. Isokawa and I. Fried, “Extracellular slow negative transient in the dentate gyrus of human epileptic hippocampus in vitro,” Neuroscience, vol. 72, no. 1, pp. 31–37, 1996. View at Publisher · View at Google Scholar · View at Scopus
  28. J. Loukkola, M. Laine, H. Ainiala et al., “Cognitive impairment in systemic lupus erythematosus and neuropsychiatric systemic lupus erythematosus: a population-based neuropsychological study,” Journal of Clinical & Experimental Neuropsychology, vol. 25, no. 1, pp. 145–151, 2003. View at Publisher · View at Google Scholar · View at Scopus
  29. R. Omdal, K. Brokstad, K. Waterloo, W. Koldingsnes, R. Jonsson, and S. I. Mellgren, “Neuropsychiatric disturbances in SLE are associated with antibodies against NMDA receptors,” European Journal of Neurology, vol. 12, no. 5, pp. 392–398, 2005. View at Publisher · View at Google Scholar · View at Scopus
  30. L. Lapteva, M. Nowak, C. H. Yarboro et al., “Anti–N-methyl-D-aspartate receptor antibodies, cognitive dysfunction, and depression in systemic lupus erythematosus,” Arthritis & Rheumatism, vol. 54, no. 8, pp. 2505–2514, 2006. View at Publisher · View at Google Scholar · View at Scopus
  31. T. Gono, Y. Kawaguchi, H. Kaneko et al., “Anti-NR2A antibody as a predictor for neuropsychiatric systemic lupus erythematosus,” Rheumatology, vol. 50, no. 9, pp. 1578–1585, 2011. View at Publisher · View at Google Scholar · View at Scopus
  32. D. N. Alfarez, O. Wiegert, and H. J. Krugers, “Stress, corticosteroid hormones and hippocampal synaptic function,” CNS and Neurological Disorders - Drug Targets, vol. 5, no. 5, pp. 521–529, 2006. View at Publisher · View at Google Scholar · View at Scopus